Exploratory IND study is intended to describe a clinical trial that
is conducted early in phase 1,
involves very limited human exposure, and
has no therapeutic or diagnostic intent (e.g., screening studies, micro dose studies).
Such exploratory IND studies are conducted prior to the traditional dose escalation, safety, and tolerance studies that ordinarily initiate a clinical drug development program.
Nwabufo obtained his B.Sc. in Biotechnology with a minor in Business Administration from the Richard Stockton University, New Jersey. Nwabufo has over four years of global experience in a variety of therapeutic areas, including cardiovascular, oncology, ophthalmology, infectious diseases, CNS, and metabolic diseases as a clinical research associate.
